Document is current
Any future updates will be listed below
-
Authors
Schreiber, Sebastian https://orcid.org/0000-0002-5665-6127
Pirpilashvili, Vakhtang
Osche, David
Mörsdorf, Philipp
Fritz, Tobias
Hawi, Harun
Müller, Sophie E.
Pizanis, Antonius
Becker, Sören L.
Pohlemann, Tim
Liodakis, Emmanouil
Orth, Marcel
-
Funding
Funding for this research was provided by:
Universität des Saarlandes
- License Information
-
More Information
Article History
Received: 10 November 2025
Accepted: 7 February 2026
First Online: 23 February 2026
Declarations
:
: SS: Grants / contracts: AO-Foundation research grant; Payment or honoraria for presentations: Pfizer DO: Grants / contracts: AO-Foundation research grant; consulting fees: Rimasys, AO Trauma; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AO Faculty Member, RimasysTF: Royalties or licenses: Elsevier; consulting fees: Rimasys, AO Trauma, Illuminoss; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Rimasys, IlluminossSLB: Participation on a Data Safety Monitoring Board or Advisory Board: Shionogi (regarding cefiderocol), Pfizer (regarding ceftazidime/avibactam and aztreonam/avibactam)TP: Grants / contracts: DFG, BMBF, AO-Foundation, Werner Siemens Foundation, Storz; Support for attending meetings and/or travel: President AO Foundation, travel costs, stipend; Patents planned, issued or pending: several alongside the project ‘smart implants’ – Saarland University; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: DGU, DGOU, DGCH, AO-Foundation; stock or stock options: IlluminossAll other authors declare that they have no conflict of interest.
